Potent Synergistic Effect of Doxycycline with Fluconazole against Candida albicans Is Mediated by Interference with Iron Homeostasis
Open accessThe DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Doxycycline was found to act synergistically with the antifungal fluconazole against Candida albicans . Combination with doxycycline converts fluconazole from fungistatic to fungicidal, prevents the onset of drug resistance, and is also effective against a clinical isolate characterized by elevated resistance to fluconazole. Investigation of the interactions between the two drugs by way of checkerboard assays indicated that doxycycline had an influence on the MIC for fluconazole, as defined by CLSI standards, only at high concentrations (200 μg/ml). However, lower concentrations were effective at eliminating residual cell growth at supra-MICs of fluconazole. Using MIC-0, defined as a drug combination resulting in optically clear wells, as an endpoint, doxycycline was found to be synergistic with fluconazole at a concentration as low as 25 μg/ml, with a fractional inhibitory concentration index of <0.5. Doxycycline-mediated growth inhibition can be reversed by externally added iron, indicating that iron depletion may account for the synergism. Consistently, we confirmed old literature data about iron-chelating activity of doxycycline. Synergism of fluconazole with doxycycline does not appear to be mediated by calcineurin, since doxycycline further aggravates the susceptibility to fluconazole of mutants lacking the catalytic or the regulatory subunits of calcineurin. Growth in the presence of fluconazole and doxycycline is restored by an elevated dosage of ERG11 in Saccharomyces cerevisiae but not in C. albicans , despite the full competence of the pathogen's protein to act as a suppressor in baker's yeast.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tolerance can be affected by several adjuvant drugs 12 , iron levels 26 , and genes involved in vacuolar protein sorting 19 , as well as calcium flux 14,27,28 .”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [26]
In the citing paper
“In addition, IRO1 (Supplementary Note 2), which is involved in iron homeostasis 26 , and VPS21, which is involved in vacuolar trafficking 19 , affected FoG and not RAD.”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [26]
In the citing paper
“Hsp90 and calcineurin are well known to affect fungal drug responses, including the cidality of azoles 26,32,42,43,70,71 .”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [26]
In the citing paper
“We showed earlier that iron metabolism is involved in regulating susceptibility to fluconazole, since addition of the iron chelator doxycycline to fluconazole-treated Candida albicans and S. cerevisiae cells reduces or even completely abolishes tolerance (7, 27).”
From Mitochondrial Cochaperone Mge1 Is Involved in Regulating Susceptibility to Fluconazole in Saccharomyces cerevisiae and Candida Species (2017) · cites this paper as [7]
In the citing paper
“The tetracycline antibiotic, doxycycline, has been shown to also drastically increase the susceptibility of C. albicans to fluconazole, due to the ability of doxycycline to chelate iron and cause iron starvation in C. albicans (Fiori and Van Dijck, 2012).”
From Iron at the Centre of Candida albicans Interactions (2018) · cites this paper as Fiori and Van Dijck, 2012
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Chopra, I., & Roberts, M. (2001) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.65.2.232-260.2001 · Cited by 4,517 · cited 1×
“Tetracyclines are antibacterial drugs that prevent the association of acylated tRNAs with the ribosome, therefore inhibiting translation (9).”
BackgroundEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“Infections by Candida albicans have been on the rise in the past decades, mostly due to changes in the clinical practice, such as the increased use of immunosuppressants and broad-spectrum antibacterial agents (26, 29, 47).”
BackgroundSherman, F. (2002) · Methods in Enzymology · doi:10.1016/s0076-6879(02)50954-x · Cited by 4,121 · cited 1×
“and uracil at appropriate concentrations (59).”
[1] Getting started with yeast
Sherman, F. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)94004-v · Cited by 4,067
Gietz, R. D., & Akio, S. (1988) · Gene · doi:10.1016/0378-1119(88)90185-0 · Cited by 2,884
Synergy, antagonism, and what the chequerboard puts between them
Odds, F. C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg301 · Cited by 2,481 · cited 2×
“sidered informative for the establishment of interactions (22, 41).”
BackgroundIsogenic strain construction and gene mapping in Candida albicans.
Fonzi, W. A., & Irwin, M. Y. (1993) · Genetics · doi:10.1093/genetics/134.3.717 · Cited by 1,687
Calcineurin: Form and Function
Rusnak, F., & Mertz, P. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1483 · Cited by 1,373 · cited 1×
“Calcineurin is inactive under normal conditions, being activated only in the presence of certain external cues (52).”
BackgroundGillum, A. M., Tsay, E. Y. H., & Kirsch, D. R. (1984) · Molecular and General Genetics MGG · doi:10.1007/bf00328721 · Cited by 1,251 · cited 14×
“For overexpression studies in C. albicans, CaERG11 was amplified from genomic DNA of strain SC5314 using primers CaERG11s (5=-CCCAAGCTTATGGCTATTGTTGAAACTGTCA-3”
ResultInfluentialMolecular Evidence for the Early Colonization of Land by Fungi and Plants
Heckman, D. S., Geiser, D. M., Eidell, B. R., Stauffer, R. L., Kardos, N. L., & Hedges, S. B. (2001) · Science · doi:10.1126/science.1061457 · Cited by 1,020 · cited 1×
“Saccharomyces cerevisiae and Candida albicans are estimated to have diverged 800 million years ago (21).”
BackgroundSanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 1×
“albicans characterized by stepwise increased tolerance to fluconazole in patients undergoing continued treatment with this drug has been documented in several cases (34, 56, 57).”
BackgroundWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612 · cited 1×
“Although certain mutations in CaERG11 (54), as well as increased CaERG11 mRNA levels (46, 61), have been associated with resistance to fluconazole in C.”
BackgroundCandida albicans: A molecular revolution built on lessons from budding yeast
Berman, J., & Sudbery, P. E. (2002) · Nature Reviews Genetics · doi:10.1038/nrg948 · Cited by 578 · cited 1×
“albicans have been greatly improved in recent times (6, 7, 40).”
BackgroundRegulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576 · cited 1×
“cerevisiae as a tool, with the aim of translating the obtained results to pathogenic species (36, 58).”
BackgroundCombination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541 · cited 2×
“sidered informative for the establishment of interactions (22, 41).”
BackgroundPerea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · cited 1×
“Although certain mutations in CaERG11 (54), as well as increased CaERG11 mRNA levels (46, 61), have been associated with resistance to fluconazole in C.”
BackgroundSanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465 · cited 1×
“Although certain mutations in CaERG11 (54), as well as increased CaERG11 mRNA levels (46, 61), have been associated with resistance to fluconazole in C.”
BackgroundAn insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432 · cited 2×
“Fluconazole and other azole antifungals, targeting ergosterol biosynthesis (23), have been extensively used in the recent clinical practice thanks to their reduced toxicity and lower cost, compared to amphotericin B in its conventional and lipidic forms, respectively (44).”
BackgroundThe changing face of epidemiology of invasive fungal disease in Europe
Lass‐Flörl, C. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01691.x · Cited by 369 · cited 1×
“Infections by Candida albicans have been on the rise in the past decades, mostly due to changes in the clinical practice, such as the increased use of immunosuppressants and broad-spectrum antibacterial agents (26, 29, 47).”
BackgroundPfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352 · cited 1×
“M27-A3 procedure for MIC determination (10), with the exception that larger inocula of 10(4) CFU/ml were used (8, 49).”
MethodSanglard, D., Ischer, F., Marchetti, O., Entenza, J., & Bille, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03495.x · Cited by 350 · cited 5×
“Hypersusceptibility of cna1 /cna1 mutants to fluconazole (55) was confirmed in our tests (Fig.”
BackgroundMethodInfluentialA Human-Curated Annotation of the Candida albicans Genome
Braun, B. R., van het Hoog, M., d'Enfert, C., Martchenko, M., Dungan, J., Kuo, A., Inglis, D. O., Uhl, M. A., Hogues, H., Berriman, M., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010001 · Cited by 342 · cited 1×
“albicans have been greatly improved in recent times (6, 7, 40).”
BackgroundCalcineurin is essential for survival during membrane stress in Candida albicans
Cruz, M. C., Goldstein, A. L., Blankenship, J. R., Del Poeta, M., Davis, D., Cardenas, M. E., Perfect, J. R., McCusker, J. H., & Heitman, J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.4.546 · Cited by 342 · cited 2×
“tion of the phosphatase activity of calcineurin by the immunosuppressants (13, 55).”
BackgroundResultA High-Affinity Iron Permease Essential for Candida albicans Virulence
Ramanan, N., & Wang, Y. (2000) · Science · doi:10.1126/science.288.5468.1062 · Cited by 336 · cited 1×
“Interestingly, transcription of the iron transporters FRE9 and FTR1—the latter required for growth under low-iron conditions (51)—is upregulated in response to exposure to fluconazole (27).”
BackgroundAlmeida, R. S., Brunke, S., Albrecht, A., Thewes, S., Laue, M., Edwards, J. E., Filler, S. G., & Hube, B. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000217 · Cited by 330 · cited 1×
“albicans Als3 in iron acquisition from host ferritin has been proposed (2).”
BackgroundAn isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1
Selmecki, A., Gerami‐Nejad, M., Paulson, C., Forche, A., & Berman, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06176.x · Cited by 325 · cited 5×
“albicans to fluconazole develops as the result of multiple genetic alterations (30, 57).”
BackgroundInfluentialGenotypic Evolution of Azole Resistance Mechanisms in Sequential Candida albicans Isolates
Coste, A., Selmecki, A., Forche, A., Diogo, D., Bougnoux, M.-E., d'Enfert, C., Berman, J., & Sanglard, D. (2007) · Eukaryotic Cell · doi:10.1128/ec.00151-07 · Cited by 305 · cited 1×
“albicans, it has become increasingly clear in recent years that decreased susceptibility to fluconazole in this fungus derives from complex genetic alterations that comprise and are possibly not limited to genomic rearrangements and deregulated expression of several genes (11, 30, 57).”
BackgroundYeast Model Uncovers Dual Roles of Mitochondria in the Action of Artemisinin
Li, W., Mo, W., Shen, D., Sun, L., Wang, J., Lu, S., Gitschier, J. M., & Zhou, B. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010036 · Cited by 304
CIp10, an efficient and convenient integrating vector for Candida albicans
Murad, A. M. A., Lee, P. R., Broadbent, I. D., Barelle, C. J., & Brown, A. J. P. (2000) · Yeast · doi:10.1002/1097-0061(20000315)16:4<325::aid-yea538>3.0.co;2-# · Cited by 303
An update on antifungal targets and mechanisms of resistance in Candidaalbicans
Akins, R. A. (2005) · Medical Mycology · doi:10.1080/13693780500138971 · Cited by 291 · cited 1×
“Fungal infections represent a challenge for clinicians, because of the scarcity and sometimes the limited efficacy of antifungal drugs (1, 44).”
BackgroundRelationship of codon bias to mRNA concentration and protein length inSaccharomyces cerevisiae
Coghlan, A., & Wolfe, K. H. (2000) · Yeast · doi:10.1002/1097-0061(20000915)16:12 · Cited by 275
Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans
Marchetti, O., Moreillon, P., Glauser, M. P., Bille, J., & Sanglard, D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2373-2381.2000 · Cited by 252 · cited 4×
“gicidal drug and eliminating trailing growth (33).”
BackgroundInfluentialRegulatory networks affected by iron availability in Candida albicans
Lan, C., Rodarte, G., Murillo, L. A., Jones, T., Davis, R. W., Dungan, J., Newport, G., & Agabian, N. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04214.x · Cited by 249 · cited 1×
“albicans (25, 50), it is possible that a similar situation occurs in S.”
BackgroundThe genetic basis of fluconazole resistance development in Candida albicans
Morschhäuser, J. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00087-x · Cited by 237 · cited 1×
“cerevisiae as a tool, with the aim of translating the obtained results to pathogenic species (36, 58).”
BackgroundBalashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225 · cited 1×
“Mutations in CaFKS1 conferring resistance to the antifungal caspofungin, for instance, have been reported to occur at a frequency of 10 8 mutations per cell per generation (4).”
BackgroundTetracycline-Inducible Gene Expression and Gene Deletion in Candida albicans
Park, Y.-N., & Morschhäuser, J. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.8.1328-1342.2005 · Cited by 188
Griffin, M. O., Ceballos, G., & Villarreal, F. J. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2010.10.004 · Cited by 186
Diethylcarbamazine-related antimicrobial activity in Mycobacterium tuberculosis-infected blood
Kitchen, L. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.241 · Cited by 183
Nakayama, H., Mio, T., Nagahashi, S., Kokado, M., Arisawa, M., & Aoki, Y. (2000) · Infection and Immunity · doi:10.1128/iai.68.12.6712-6719.2000 · Cited by 157
Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species
Cantón, E., Pemán, J., Viudes, A., Quindós, G., Gobernado, M., & Espinel-Ingroff, A. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00525-4 · Cited by 149 · cited 2×
“M27-A3 procedure for MIC determination (10), with the exception that larger inocula of 10(4) CFU/ml were used (8, 49).”
BackgroundMethodPrasad, T., Chandra, A., Mukhopadhyay, C. K., & Prasad, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00653-06 · Cited by 149 · cited 3×
“albicans (25, 50), it is possible that a similar situation occurs in S.”
BackgroundMarr, K. A., White, T. C., van Burik, J. H., & Bowden, R. A. (1997) · Clinical Infectious Diseases · doi:10.1086/515553 · Cited by 145 · cited 2×
“albicans characterized by stepwise increased tolerance to fluconazole in patients undergoing continued treatment with this drug has been documented in several cases (34, 56, 57).”
BackgroundMiller, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3577 · Cited by 130 · cited 1×
“subcloned into SmaI pBEVY-GL (35), creating plasmid pAFC99a.”
MethodGFP as a quantitative reporter of gene regulation in Candida albicans
Barelle, C. J., Manson, C. L., MacCallum, D. M., Odds, F. C., Gow, N. A. R., & Brown, A. J. P. (2004) · Yeast · doi:10.1002/yea.1099 · Cited by 125 · cited 3×
“The resulting plasmids are named pAFC89b (ACT1p-CaERG11) and pAFC92a (PCK1p-CaERG11).”
BackgroundEnjalbert, B., Rachini, A., Vediyappan, G., Pietrella, D., Spaccapelo, R., Vecchiarelli, A., Brown, A. J. P., & d'Enfert, C. (2009) · Infection and Immunity · doi:10.1128/iai.00223-09 · Cited by 120 · cited 3×
“The amplified fragment was subcloned with HindIII-NheI, replacing the luciferase gene, in plasmid Cip10::ACT1p-gLUC59 (15), and in plasmid pPCK1-GFP (5), replacing the green fluorescent protein (GFP) gene.”
BackgroundGenetics of Candida albicans, a Diploid Human Fungal Pathogen
Noble, S. M., & Johnson, A. D. (2007) · Annual Review of Genetics · doi:10.1146/annurev.genet.41.042007.170146 · Cited by 115 · cited 1×
“albicans have been greatly improved in recent times (6, 7, 40).”
BackgroundChemical and Biological Dynamics of Tetracyclines
Nelson, M. L. (1998) · Advances in Dental Research · doi:10.1177/08959374980120011901 · Cited by 111
Grenier, D., Huot, M.-P., & Mayrand, D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.763-766.2000 · Cited by 109 · cited 1×
“Grenier and collaborators (19) proposed”
Molecular genetic analysis of azole antifungal mode of action
Kelly, S. L., Arnoldi, A., & Kelly, D. E. (1993) · Biochemical Society Transactions · doi:10.1042/bst0211034 · Cited by 106 · cited 1×
“Fluconazole and other azole antifungals, targeting ergosterol biosynthesis (23), have been extensively used in the recent clinical practice thanks to their reduced toxicity and lower cost, compared to amphotericin B in its conventional and lipidic forms, respectively (44).”
BackgroundMallory, J. C., Crudden, G., Johnson, B. L., Mo, C., Pierson, C. A., Bard, M., & Craven, R. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1669-1679.2005 · Cited by 102 · cited 2×
“On the other hand, while strong suppression of susceptibility to fluconazole upon overexpression of ERG11 in baker’s yeast is reported in this article and has also been described by others (24, 32), a similar clear-cut correlation has not been established in C.”
BackgroundPfaller, M. A., Messer, S. A., Karlsson, Å., & Bolmström, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.9.2586-2589.1998 · Cited by 99 · cited 3×
“Fluconazole MIC testing using Etest strips has been reported to deliver results comparable to those obtained using the broth microdilution method, within a 2-dilution margin of discrepancy (48).”
BackgroundMethodInfluentialMacCallum, D. M., Coste, A., Ischer, F., Jacobsen, M. D., Odds, F. C., & Sanglard, D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01645-09 · Cited by 98 · cited 2×
“albicans, it has become increasingly clear in recent years that decreased susceptibility to fluconazole in this fungus derives from complex genetic alterations that comprise and are possibly not limited to genomic rearrangements and deregulated expression of several genes (11, 30, 57).”
BackgroundA general suppressor of RNA polymerase I, II and III mutations in Saccharomyces cerevisiae
Stettler, S., Chiannilkulchai, N., Denmat, S. H., Lalo, D., Lacroute, F., Sentenac, A., & Thuriaux, P. (1993) · Molecular and General Genetics MGG · doi:10.1007/bf00281615 · Cited by 97 · cited 1×
“In order to identify multicopy suppressors of fluconazoledoxycycline susceptibility, BY4742 was transformed with a yeast genomic library in a 2 m plasmid (60), and transformations were plated on minimal medium containing fluconazole plus doxycycline.”
MethodRyan, M., Usman, A., Ramamurthy, N., Golub, L., & Greenwald, R. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373598 · Cited by 96
Leuker, C., Sonneborn, A., Delbrück, S., & Ernst, J. F. (1997) · Gene · doi:10.1016/s0378-1119(97)00069-3 · Cited by 93 · cited 1×
“Most of them, such as the PCK1 and the MAL2 promoters, allow conditional expression/repression of the gene of interest upon incubation of cells in growth media containing the repressing or the activating carbon source (3, 28).”
BackgroundSupplement: Trends in invasive Candida infections and their treatment: focus on echinocandins
(2009) · Current Medical Research and Opinion · doi:10.1185/03007990902990817 · Cited by 89 · cited 1×
“Infections by Candida albicans have been on the rise in the past decades, mostly due to changes in the clinical practice, such as the increased use of immunosuppressants and broad-spectrum antibacterial agents (26, 29, 47).”
BackgroundMaesaki, S., Marichal, P., Hossain, M. A., Sanglard, D., Vanden Bossche, H., & Kohno, S. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.6.747 · Cited by 77
Craven, R. J., Mallory, J. C., & Hand, R. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706770200 · Cited by 67
Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi
Oliver, B. G., Silver, P. M., Marie, C., Hoot, S. J., Leyde, S. E., & White, T. C. (2008) · Microbiology · doi:10.1099/mic.0.2007/013805-0 · Cited by 63
Kontoyiannis, D. P., Sagar, N., & Hirschi, K. D. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2798 · Cited by 56
Odds, F. C., Abbott, A. B., Pye, G., & Troke, P. F. (1986) · Medical Mycology · doi:10.1080/02681218680000461 · Cited by 42 · cited 2×
“Odds and collaborators (42) observed a strong reduction of the MIC for fluconazole and elimination of trailing growth by doxycycline when they used diagnostic susceptibility test agar medium, but not when tissue culture-based medium was used.”
BackgroundLepak, A., Nett, J., Lincoln, L., Marchillo, K., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1311-1319.2006 · Cited by 42 · cited 1×
“Interestingly, transcription of the iron transporters FRE9 and FTR1—the latter required for growth under low-iron conditions (51)—is upregulated in response to exposure to fluconazole (27).”
BackgroundDu, W., Coaker, M., Sobel, J. D., & Akins, R. A. (2004) · Current Genetics · doi:10.1007/s00294-004-0499-3 · Cited by 29 · cited 1×
“albicans reports a moderate resistance in cells with 11-fold increased levels of CaERG11 (14).”
BackgroundSusceptibility Testing Methods of Antifungal Agents
Ernst, E. J. (2005) · Humana Press eBooks · doi:10.1385/1-59259-943-5:003 · Cited by 7 · cited 4×
“Since in these experiments, determination of the 99.9% killing activity that classically defines the minimal fungicidal concentration (MFC) (16) was not possible, the MFC could not be used as an endpoint.”
MethodInfluential
Research works printed but not linked: 2
- BackenAC . 2000. Evaluation of the CaMAL2 promoter for regulated expression of genes in Candida albicans. Yeast 16:1121–1129. · DOI · Paper page
- LewisRE. 2009. Overview of the changing epidemiology of candidemia. Curr. Med. Res. Opin. 25:1732–1740.
Cited by
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
Recent insights into Candida albicans biofilm resistance mechanisms
Mathé, L., & Van Dijck, P. (2013) · Current Genetics · doi:10.1007/s00294-013-0400-3 · Cited by 271
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270
Geddes‐McAlister, J., & Shapiro, R. S. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 159
Liu, S., Hou, Y., Chen, X., Gao, Y., Li, H., & Sun, S. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.12.009 · Cited by 164
Metadata
- Authors
- Fiori, A., & Van Dijck, P.
- Affiliations
- Vlaams Instituut voor Biotechnologie (BE)
- Department of Molecular Microbiology, Flanders Institute for Biotechnology (VIB), Katholieke Universiteit Leuven, Leuven, Belgium
- ORCID
- Fiori, Alessandro
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-07
- Volume
- 56
- Issue
- 7
- Pages
- 3785-3796
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3393430
- OpenAlex
- W2076426605
- Cited by
- 112
- References
- 65
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 13 · 2019: 13 · 2018: 8 · 2017: 13 · 2016: 9 · 2015: 6 · 2014: 10 · 2013: 7
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- doxycycline, fluconazole, Candida albicans, drug synergy, iron homeostasis, iron chelation, fungicidal activity, antifungal resistance, calcineurin, ERG11, checkerboard assay
- MeSH terms
- Candida albicans, Cytochrome P-450 Enzyme System, Doxycycline, Drug Synergism, Homeostasis, Iron, Microbial Sensitivity Tests, Saccharomyces cerevisiae, Fluconazole, Saccharomyces cerevisiae Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.